Multiple Myeloma Treatment Market is a cancer of plasma cells. Plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells which includes T cells and B cells that work together to fight against infections and other diseases. Lymphocytes are one of the important types of white blood cells (WBCs) in the immune system. Different types of lymphocytes are present in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.
Multiple Myeloma Treatment Market to grow 11.0% CAGR during the Forecast Period 2018 to 2023
global multiple myeloma market is anticipated to grow by an increase in aging population, increase in healthcare expenditure, and increasing use of novel cancer drugs in the market, whereas increasing prevalence of disease along with growing elderly population is the prime factor to drive the growth of this market during the forecast period. It has also been observed that the upcoming drug pipeline of multiple myeloma is promising. Other factors such as biological drugs and stem cell therapies are expected to drive the market in the future. The key players in the market are accelerating the research and development activities for multiple myeloma treatment.
Get Sample Research Report at https://www.marketresearchfuture.com/sample_request/6818
Key players:
Some of the key players in the global multiple myeloma treatment market are Celgene Corporation,
Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals,
Amgen, Inc., Genzyme Corporation, Juno Therapeutics, Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Innate Pharma SA, and Celldex Therapeutics, Inc., Onyx Pharmaceuticals, Pfizer, Takeda Pharmaceuticals.
Global Multiple Myeloma Treatment Market Research Report: By Treatment (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Corticosteroids, Interferon, and Others), End User (Hospitals, Clinics, Independent Pharmacies, and Others)—Forecast till 2023
Global multiple myeloma treatment is further segmented into treatment types and end-users. Based on treatment types the market is segmented into chemotherapy, corticosteroids, interferon, stem cell transplant, and radiation therapy. Chemotherapy is further sub-segmented into bendamustine (treanda), cyclophosphamide (Cytoxan), doxorubicin (adriamycin), etoposide (vp-16), liposomal doxorubicin (Doxil), melphalan (Alkeran, evomela), vincristine (Oncovin). On the basis of end-user global multiple myeloma treatment market is further segmented into hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others.
Global Multiple Myeloma Treatment Market, by Treatment
- Chemotherapy
- Bendamustine (Treanda)
- Cyclophosphamide (Cytoxan)
- Doxorubicin (Adriamycin)
- Etoposide
- Liposomal doxorubicin (Doxil)
- Melphalan (Alkeran, Evomela)
- Vincristine (Oncovin)
- Corticosteroids
- Interferon
- Stem Cell Transplant
- Radiation Therapy
Global Multiple Myeloma Treatment Market, by End User
- Hospitals
- Clinics
- Independent pharmacies
- Others
Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/multiple-myeloma-treatment-market-6818
Geographically, North America is expected to hold the largest share in global multiple myeloma treatment market due to key driving factors such as rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure.
Europe has been dominating the multiple myeloma treatment market owing to the faster approval rates and favorable healthcare policies and the presence of major players in this region. Higher prevalence of multiple myeloma in developed economies is driving the growth of the Europe market.
Asia-Pacific is expected to show exponential growth due to rising awareness associated with cancer diagnosis and developing healthcare infrastructure is responsible for high accessibility to modern technology.
Furthermore, factors such as increased healthcare infrastructure and improved healthcare reimbursement policies are responsible for the growth of multiple myeloma treatment market in the Middle East and Africa.
Inquire for Discount at https://www.marketresearchfuture.com/check-discount/6818
Intended Audience
- Manufacturers and Suppliers
- Hospitals and clinics
- Laboratories and Associations
- Research institutes
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
Your information will never be shared with any third party.